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I. Abstract:  
Observing and designing the in vivo distribution and localization of therapeutic 
nanoparticles is an essential aspect of developing and understanding novel nanoparticle-
based medical treatments. This study investigates novel PEGylated Iodine-based 
nanoparticles (INPs), an alternate composition to the more widely researched gold 
nanoparticles (AuNPs), which may help avoid adverse effects associated with AuNPs, such 
as potential toxicity and skin discoloration, when used in similar applications. Determining 
the localization of the novel INPs within murine brains containing human glioma U-1242MG 
cells is critical in assisting the development of radiation dose enhancement therapy for this 
aggressive cancer. Radiation dose enhancement utilizes the increased radiation absorption of 
the INPs and subsequent increased electron and photon scattering to increase the therapeutic 
effect and possibly help reduce the radiation dose administered. This study serves to 
qualitatively and semi-quantitatively determine the distribution of the novel INPs within the 
murine brain, the tumor region, and at the cellular level within the tumor. This is 
accomplished through immunofluorescence staining and light and confocal microscopy, 
probing for CD31 (PECAM1), an endothelial cell marker, poly(ethylene glycol) (PEG), a 
nanoparticle marker, DAPI, a nucleus marker, and tdTomato, a fluorescent protein expressed 
by the implanted U-1242MG cells. The imaging at 10X and 63X magnification yielded 
evidence that the PEGylated INPs are distributed in and around the tumor to a much greater 
extent than elsewhere in the brain and there is some propensity for the INPs to localize in the 
vasculature far from the tumor region as well as within the tumor region. At the cellular level 
the INPs are not regularly taken up by cells and introduced into the cytoplasm within 24 
hours of the last injection. Therefore, this study is relevant to radiation therapy in that it 
further characterizes the behavior of INPs in glioma containing murine brains, and from the 
data on where these particles exist, researchers can eventually develop a correlation of 
therapy results with INP localization at the cellular level to better develop patient treatments. 
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II. Introduction: 
Radiation Dose Enhancement: 
Radiation therapy is a fundamental element in the treatment of brain tumors and is 
frequently used in conjunction with surgical excision and chemotherapy. In regards to 
glioblastoma multiforme (GBM), radiotherapy is considered the standard of care when 
combined with the chemotherapeutic temozolomide [1]. In fact, radiation therapy has the 
potential to be useful as a curative treatment method in 25 % of all new cancer cases, and as 
palliative care in an additional 25 % of new diagnoses [2]. Nonetheless, though radiation 
therapy can kill malignant cells, and slow or halt the growth of tumors, by inducing DNA 
damage which interrupts the cellular division process ultimately leading to apoptosis or 
latency [3], it can also damage or kill healthy brain tissue and ultimately lead to radiation 
necrosis [2, 4, 5]. Radiation necrosis, which is essentially healthy brain tissue death 
following radiation therapy, often appears 6 months to 2 years after treatment due to the 
delayed cellular response to DNA damage acquired during radiation therapy in healthy 
tissues [4]. In particular, the endothelial cells of smaller blood vessels are most often affected 
and their death recruits lymphocytes and macrophages, which in turn trigger a cascade of 
cytokine activity and an inflammatory immune response. Ultimately, the inflammation 
induces new, though irregular vascular growth very prone to thrombosis and hemorrhage, 
leading to ischemic injury in healthy brain tissues [4]. Additionally, there are significant side 
effects associated with radiation necrosis including headache, drowsiness, memory loss, 
personality change, seizures, and even eventual death, while there are few well-studied 
treatment options for the condition [4].  
	 Billings 5 
One possible approach under development to mitigate the damage to healthy tissue is the 
use of heavy-atom-based nanoparticles to amplify radiation doses within tumors while 
delivering a less toxic dose to normal tissues [6, 7, 8, 9]. If heavy-atom based nanoparticles 
are loaded into tumors by any means, radiation dose enhancement is possible due to the 
increased absorbance of X-rays and subsequent increase in scattered electrons, ions, radicals, 
and other reactive chemical species in tissues due to the higher concentrations of heavy 
atoms present in the tumor [6]. Therefore, by exploiting the enhanced permeability and 
retention (EPR) effect of nanoparticles within tumors due to the malformed and leaky 
vasculature present in some tumors, nanoparticles can be distributed throughout a tumor by 
minimally invasive intravenous injection [10]. Thus, as researchers have shown dose 
enhancement with gold nanoparticles or iodine contrast media [6, 7, 8, 9], our lab seeks to 
demonstrate radiation dose enhancement with novel, PEGylated iodine-based nanoparticles. 
The INPs have the potential to avoid the renal toxicity of iodinated molecules [11] and the 
various disadvantages of gold nanoparticles including discoloration of the skin and the 
possibility of toxicity of gold nanoparticles presented in some studies but not in others 
[reviewed in 12]. 
a. PEGylation of Nanoparticles: 
Due to the small size and high surface area to volume ratio of nanoparticles, there is a 
substantial fraction of the total number of atoms of the nanoparticles at the surface, with 
uncoordinated bonds. This results in a very high surface energy for small particles and the 
subsequent aggregation and adsorption of other nanoparticles and molecules in order to 
reduce the fraction of atoms with “dangling bonds”, and therefore reduce the overall surface 
energy. In order to mitigate this effect and retain nanoparticle size, ligands are often attached 
	 Billings 6 
to nanoparticles to resist protein adsorption and particle aggregation in an in vivo 
environment. The industry standard ligand that has emerged for this function has been 
poly(ethylene glycol) (PEG), a polyether which has been shown to be hydrophilic and  
bioinert [14, 16]. These properties, as well as the polymer’s size allow particles with attached 
PEG ligands to increase their solubility and hydrodynamic size by increasing the amount of 
coordination sites for the aqueous solvation layer, allowing the avoidance of renal clearance, 
and a subsequent increase in circulation time [15]. Likewise, the bioinert behavior of PEG 
allows it to be used as a “stealth” agent on nanoparticles and other molecules, allowing 
PEGylated particles to avoid the immune system response as well as non-specific cellular 
uptake mostly by the reticuloendothelial system of the liver (RES), further increasing the 
circulation time [14, 15, 17]. This “stealth” effect is possible because the hydrophilic 
polymers resist opsonin binding, therefore resulting in fewer nanoparticles marked for 
endocytosis [18]. With enhanced circulation times, more drugs or nanoparticles are capable 
of being dispersed or deposited in the desired location, selected for by additional specific 
surface protein binding ligands or in the case of some tumors, the already existing, leaky 
vasculature, which enables blood borne molecules to enter the tumor interstitium [19, 20].  
 The novel iodine-based nanoparticles used in this study have been PEGylated to exploit 
the same phenomena mentioned above. Further, the PEG ligands are the molecules that are 
probed for with immunofluorescence imaging to determine the localization of the 
nanoparticles. 
b. Human Glioma U-1242MG: 
The model cell strain used in this experiment was U-1242MG, a human glioma. As a 
glioma, or a cancer arising from the glial cells of the brain, these cells are adapted to living in 
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brain tissue and thus are capable of rapid growth and invasion of healthy tissue. These 
tumors, referred to as glioblastomas when displaying highly invasive and proliferative 
behavior, are noted for having hyperplastic blood supplies as well. It is worth noting that due 
to the ability and tendency of U-1242MG cells to grow amongst healthy brain tissue, 
symptoms are not generally observed until the tumor is already quite large [21].  
In this study, the implanted U-1242MG cells were transduced by Northwestern 
University to express the protein firefly luciferase as well as the fluorescent protein 
tdTomato. Hence the tumor could be monitored while growing with bioluminescence and 
viewed histologically by fluorescent microscopy.  
c. Previous Research and Results 
There have been several studies concerning the localization of PEGylated nanoparticles, 
including gold-based and polymer-based nanoparticles [22, 23]. The localization on the 
intercellular and intracellular level is ultimately dependent on the specific uptake proteins 
ligated to the nanoparticles as well as the final diameter of the nanoparticles [22]. In 
particular, the findings reported concerning PEGylated gold nanoparticles (AuNPs) stated 
that 2.4 nm AuNPs localized in the nucleus once internalized, 5.5 – 8.2 nm AuNPs localized 
in the cytoplasm, and nanoparticles greater than 16 nm in diameter were not permitted into 
the cells and localized at the cellular periphery [22]. This study aims to characterize and 
compare the localization of the novel INPs with the results in these findings since there are 
similarities in the PEG nanoparticle surface, but differences in the core composition. Lastly, 
the novel INPs do not have specific cellular uptake proteins attached and therefore will not 
extensively use receptor-mediated endocytosis.  
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III. Materials & Methods:  
a. Materials: 
• Implantation 
• 8 week old, female, athymic nude mice; n = 3 
• U-1242MG cells expressing tdTomato fluorescent protein 
• 1-microliter syringe 
• Drill 
• Scalpel 
• Surgical Glue 
• Ketamine/Xylazine anaesthetic  
• Alcohol swabs, Betadine, Gauze pads 
• Injection 
• PEGylated Iodine-based nanoparticles (INP) 
• 25 gauge syringe 
• Tail vein mouse restrainer 
• Sectioning 
• Cryomatrix 
• Glass microscope slides 
• Pink slide tape/Japanese tape 
• Leica CM3050 S Research Cryostat 
• Staining 
• Primary Antibodies 
• Goat-anti-Mouse/Rat CD31 diluted 1:100 in 1% BSA 
solution from R&D AF3628 
• Rabbit-anti-PEG diluted 1:500 in 1% BSA solution from 
Abcam ab51257 
• Secondary Antibodies 
• Donkey-anti-Rabbit conjugated with Alexa Fluor 488 
diluted 1:400 in 1% BSA solution from Invitrogen a21206 
• Donkey-anti-Goat conjugated with Alexa Fluor 647 diluted 
1:200 in 1% BSA solution from Life Technologies a21447 
• Solutions 
• Washing solution (phosphate-buffered saline (PBS)) 
• Blocking Solution (1:10 dilution of PowerBlock in PBS) 
• Antibody Diluent (1% Bovine Serum Albumin in PBS) 
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• Coverslip Mounting Solution (1:1000 Hoescht 33342 in 
50% v/v Glycerol in PBS) 
• Coplin Jars 
• 1000 microliter, 100 microliter, 20 microliter, and 5 microliter 
micropipettes 
• Imaging 
• Fluorescence Light Microscope – Zeiss Axio Observer Z1 
• Confocal Microscope – Zeiss LSM 880 
• Zen Black/Zen Blue imaging software & Fiji image processing 
software 
b. Methods:  
Implantation of the human glioma U-1242MG cells into the brains of three, 8 week 
old, female, athymic, nude mice: Mice were sedated with an intraperitoneal injection of 
the ketamine/xylazine drug cocktail of approximately 90 mg/kg and 5 mg/kg dosages 
respectively. Upon complete sedation determined by the lack of a pedal or toe pinch 
reflex, a dorsal incision was made on each mouse’s head to reveal the skull beneath. 
Next, with the 450-micrometer micro-drill, a hole was made through each skull and dura 
revealing the left hemisphere of the brain. A 27 gauge needle fitted with a 2.5 – 3 mm 
plastic, depth limiting collar connected to a 1-microliter syringe previously loaded with 
~100,000 U-1242MG cells was then introduced carefully into each opening. The cells 
were then injected over the course of 1 minute and a total volume of 1 microliter. One 
minute later the needle was then removed and the skin was sutured using surgical glue to 
close the incisions.  
Tumor Monitoring and INP Administration: The implanted tumors were then 
monitored using the In Vitro Imaging System (IVIS) Spectrum machine for 2-3 weeks to 
track tumor growth. After successful tumor growth indicated by a set signal threshold 
from the tumor, the mice were then injected 4 times with INP at 1.75 g I/kg body weight 
over 48 hours, with two injections 3 hours apart on two consecutive days. 24 hours 
	 Billings 10 
following the final injection the mice were deeply anesthetized and subjected to perfusion 
fixation. 
Perfusion Fixation and Tissue Harvesting: Each mouse was anesthetized with the same 
surgical dose of the ketamine/xylazine cocktail described previously and monitored using 
the to pinch method for full anesthesia. Upon full anesthesia, each mouse was secured on 
its back with its limbs spread away from its body. A transverse incision was made 
through the skin of the abdomen followed by the muscle layer into the abdominal cavity 
of the mouse, careful to avoid any internal organs. Next, curved, blunt scissors were used 
to cut the ribs from the lateral incision toward the collarbone on each side. Tissue 
connecting the heart to the sternum was carefully trimmed away allowing for the rib cage 
to be held in place over the animal’s head using a hemostat. A 15 gauge blunt needle was 
then introduced through the left ventricle into the ascending aorta and the right atrium 
was cut to allow for blood to drain from the circulatory system. Immediately following 
the laceration of the atrium, PBS was delivered through the needle for approximately 10 
– 15 seconds followed by 10% formalin. This fluid was administered until the mouse was 
fully stiff and no further blood drained from the atrium. The brains were then harvested 
by resecting the skull and stored for 24 hours in a 10% formalin solution at 4° C. The 
brains were transferred to a 30% sucrose solution overnight at 4° C. Finally, the brains 
were cut laterally, mid-tumor and were submerged in Cryomatrix and frozen in dry ice 
cooled isopentane. 
Cryosectioning: Once the blocks were prepared, microscope slide sections were 
prepared using the Leica CM3050 S Research Cryostat. A selected block was mounted 
onto a chilled pedestal, and aligned with the blade of the machine to ensure consistent 
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and level 7-micrometer sections with every cut. For each specimen sample, a section of 
microscope slide tape was applied to the mounted block and firmly secured with the use 
of a roller. The sample was then taken and quickly transferred to a chilled glass 
microscope slide. This process was repeated for the desired number of sections from 
various regions of the brains. The samples were then cross-linked to the slides with UV 
light.  
Immunofluorescence Staining: Enough sections were taken to provide a series of 
controls for the staining protocol. This included sections stained with no antibodies, only 
primary antibodies, only secondary antibodies, individual combinations of primary and 
secondary, and all antibodies. Previous work in our lab has ruled out any non-exclusive 
and undesired antibody-antibody interactions as well as non-specific antigen labeling 
when using this specific set of antibodies. However, an isotype antibody control was not 
performed followed by a secondary antibody to determine the presence of any 
background signal. The same staining protocol was used for all slides and all antibody 
combinations and is described below.  
All slides were placed in Coplin jars and rehydrated in PBS for 10 minutes. The slides 
were then removed and dried with Kimwipes, avoiding contact with any tissue on the 
slide. Next, each section was blocked using 100 microliters of the blocking solution, 
applied with a 100-microliter micropipette, ensuring full coverage of each individual 
section, avoiding tissue contact with the pipette. After 30 minutes, the blocking solution 
was removed by tilting each slide perpendicular to the work surface and tapping gently to 
dislodge the liquid. The slides were then placed back in the Coplin jars and washed in 
PBS for 5 minutes to remove any excess blocking solution. The slides were then 
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removed, dried, and prepared for the primary antibody addition. First, the primary 
antibody solution containing both primary antibodies was prepared in the proper dilution 
ratio for each antibody. Each section was then stained according to its series designation 
with approximately 80 microliters of its given antibody solution. To sections serving as 
controls and receiving neither of the two primary antibodies, a 1% BSA solution was 
applied. All slides were then incubated overnight at 4°C in a humidified environment.  
Following the primary antibody incubation, the antibody solutions were removed and 
the slides were placed in Coplin jars and washed in PBS 3 times for 5 minutes each and 
then dried as described above. Similarly, one solution was prepared containing both 
secondary antibodies in their proper dilution ratios. Each section was then stained 
according to its series designation, again with approximately 80 microliters of staining 
solution. To sections receiving neither of the two secondary antibodies, 1% BSA in PBS 
was applied. The slides were then placed in a humidified environment and allowed to 
incubate at room temperature for 60 minutes. The slides were the washed 3 times in PBS 
for 5 minutes each wash and then dried and prepared for coverslip mounting.  
The coverslip mounting media was prepared by adding 500 microliters of glycerol to 
500 microliters of PBS in a 3 mL microcentrifuge tube. This solution was thoroughly 
mixed using a test tube vortex mixer. One microliter of the Hoescht 33342 stain was then 
added to the glycerol-PBS mixture and the solution was mixed using the vortex mixer 
again. Finally, using a 20-microliter micropipette, about 6 to 8 microliters of the prepared 
coverslip mounting media was applied to each section. A glass coverslip was then slowly 
lowered onto each slide taking care to trap as few air bubbles as possible. Lastly, using 
Kimwipes, any excess mounting media was removed by gently patting the edges of each 
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slide, taking care to not smudge or smear any solution across either glass surface. The 
prepared slides were then stored at -20°C in sealed container until they were imaged.  
Fluorescence Imaging: All imaging was performed using either the Zeiss Axio Observer 
Z1 fluorescence light microscope or the Zeiss LSM 880 confocal microscope and images 
were processed using the Zen Blue software and the open-source software variant of 
ImageJ called Fiji. Images were taken in several formats including 10X magnification 
tile-scans and 20X magnification single frame images using the Zeiss Axio Observer Z1, 
and 63X magnification single frame images and 63X magnification z-stacks using the 
Zeiss LSM 880 confocal microscope. 
IV. Results:  
a. 10X Magnification Tile Scan: 
In order to investigate the general localization of the novel INP, a tile-scan of the 
entire brain section containing the tumor region in the left hemisphere with a tumor free 
right hemisphere was taken on the Zeiss Axio Observer Z1. This tile-scan, conducted at 
10X magnification, allowed moderate resolution over the entire surface with a white 
arrow indicating the center of the main tumor mass. The images demonstrated a much 
greater PEG signal in the hemisphere with implanted U-1242MG cells, as is evident in 
Figure 1d. Additionally, an overall increase in CD31 signal was obtained in and around 
the tumor region (Figure 1c).  
In the region of interests marked in colored boxes in Figure 1b, the tile scan 
image is utilized to determine if the localization of PEG occurs at sites exhibiting CD31 
signals. In the first region of interest marked by the red box in Figure 1b, an area lying 
along the midline of the brain far from the tumor, there is a strong correlation of PEG and 
CD31 signal, with little PEG signal outside of the regions exhibiting CD31 signal. This is 
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evident in Figure 2, and further in Figure 3, which shows the PEG stain more 
completely mapping the small vessels in the brain than the CD31 stain. This might be 
possible because more PEG molecules were trapped and exposed to the immunostaining 
antibodies than CD31 molecules, which are present at the intercellular junction sites, 
which may not all be exposed to the surface, or it is possible the antibody binding affinity 




































Figure 1a & 1b: 10X Tile Scan of murine brain with tumor present as 
well as INP. The image shows nuclei colored blue (a), U-1242MG cells 
colored red (b), endothelial cell marker CD31 colored cyan (c), and PEG 
colored green (d). The white arrow points to the center of the tumor.  



























Figure 1c & 1d: 10X Tile Scan of murine brain with tumor present as well 
as INP. The image shows nuclei colored blue (a), U-1242MG cells colored 
red (b), endothelial cell marker CD31 colored cyan (c), and PEG colored 
green (d). The white arrow points to the center of the tumor.  
c)	 d)	
























Figure 2: Region of interest 1 (red box in Figure 1c) outside of the tumor showing 
localization of PEG (right) in regions with CD31 endothelial marker staining (left). The 
channels for the U-1242MG cells and the cell nuclei stains were omitted because there 
was no tumor signal and cell nuclei were uniformly present at this magnification.   
Figure 3: Region of interest 2 outside of the tumor (orange box) showing PEG (right) 
and CD31 (left) co-localization. In fact, in this image, the anti-PEG staining seems to 
map the vasculature of the section better than the CD31 staining, likely due to the much 
higher concentration of PEG antigens and subsequent contrast of the PEG stain.  
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In Figures 4 & 5 regions of interest within the tumor were explored using 10X 
magnification to determine any correlation of PEG localization with CD31 expression within the 
tumor region, as well as in relation to tdTomato expressing U-1242MG cells and non-expressing 
native tissues. As is evident in Figure 4, there is a large signal indicating near uniform PEG 
distribution throughout the tumor, among both cancerous and non-cancerous cells. Likewise, in 
Figure 5 several large vessels are clearly present, formed within tumor cell clusters, and 
exhibiting significant signal from both CD31 and PEG staining. Additionally, Figure 6 shows a 
10X magnification image with CD31, PEG, nuclei, and U-1242MG cells individually and 
overlaid. The result is a clear display of a high amount of CD31 antigens, a near uniform 
distribution of cell nuclei, a heterogeneous distribution of U-1242MG cells, displaying the 
invasive nature of this strain, and a near uniform distribution of PEG throughout this region. 
Nonetheless, the localization of the PEG is not clear at 10X magnification at the cellular level. 
In order to address the ambiguity of the localization of the PEG signals at 10X 
magnification, a series of z-stack confocal microscopy images were taken on the Zeiss LSM 880 
microscope at 63X magnification. Figure 7 displays 3 levels of the stack selected to display a 
change in the PEG signal as the plane of focus proceeded into the center of a layer of cells. 
Additionally, in Figure 7 a region of interest containing a strong signal for CD31 and PEG is 
highlighted. From this series it appears that the PEG signal is strongest at the surface and exterior 
of cells as well as in vessels and voids within the tissue. As this z-stack proceeded, the PEG 
signal further decreased, appearing only along the edges before increasing much like the top 
plane. A possible explanation for this behavior is the inability for the antibodies to effectively 
penetrate and stain intracellular PEG, which would alternatively explain why the PEG was not 
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seen localized in the cells, however as discussed later a membrane permeabilizer used in a 
staining protocol may confirm or deny this theory.  
Finally, a quantitative analysis of the colocalization of the different signals was 
performed using the Pearson’s Correlation Coefficient (PCC). This scale disregards signal 
intensity and simply compares signal presence at the same pixels in an image over different 
channels. The scale is from -1 to 1, with -1 signifying perfect antilocalization, 0 signifying no 
correlation, and 1 signifying perfect correlation. Using Figure 6, it was found within the tumor 
there was a PCC of -0.01 between the tumor cells and the PEG signal, indicating no specificity, 
and a PCC of 0.3 between the PEG and CD31 signals, indicating low to moderate colocalization 
specificity. Additionally, the PEG and CD31 PCC values were calculated for Figures 2 through 
5 to determine the colocalization propensity of PEG with CD31. PCC values outside the tumor in 
the regions of interest were 0.47 and 0.63 for Figure 2 and 3 respectively, indicating moderate 
colocalization. PCC values within the tumor in the regions of interest displayed in Figures 4 and 
5 were 0.75 and 0.65 respectively indicating a strong correlation between the localization of 
CD31 and PEG signals. At 63X using Figure 7 the PCC value between PEG and CD31 was 
0.42, the PCC value between PEG and tdTomato was 0.05, and the PCC between PEG and 
nuclei was -0.10. It should be noted that the slight background present in these images is 
considered using the PCC metric, and the backgrounds of tdTomato was significant, bringing the 
PCC between PEG and tdTomato closer to 0. The results are summarized in the bar graph at the 
end of the results section.  
Lastly, several calculations were done using Figure 1 to determine the fractional area 
occupied by the tumor and the fraction of the PEG signal this area contained. Ultimately the 
tumor occupied about 16.5 percent of the sectional area and contained approximately 40 percent 
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of the PEG signal. This demonstrates the EPR effect and that PEG is loaded in the tumors more 
than outside of the tumor region. However, it also shows that about 60 percent of the signal 





















Figure 4: Region of interest 1 
inside of the tumor (yellow box). 
This region shows extensive PEG 
accumulation within the tumor (top 
right), moderate and near uniform 
CD31 expression (top left), and 
heterogeneous tdTomato 
expression (right), demonstrating 
the invasive nature of the U-
1242MG cells and their ability to 
grow amongst healthy tissue.  

















Figure 5: Region of interest 2 
within the tumor (purple box of 
1b). As in Figure 4, this image 
supports extensive PEG 
accumulation within the tumor (top 
right) around both the native cells 
and U-1242MG cells. Additionally, 
the top left image shows significant 
CD31 staining indicating large 
blood vessels present. The PEG 
stain in the top right demonstrates 
localization in and around these 
larger vessels.  
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Figure 6: 10X magnification 
images of the tumor region 
showing CD31 (top left), nuclei 
(middle left), U-1242MG (middle 
right), and PEG (top right). 
Additionally, a composite image of 
all 4 channels is shown bottom 
right. These images show PEG in 
both healthy and cancerous tissue 
withing the tumor. 
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Figure 7: 63X z-stack images of the tumor 
region showing images taken 6 layers apart. All 
three show PEG (green), nuclei (blue), CD31 
(magenta), and U-1242MG cells (red). In the 
top left image there is a vessel with a large 
signal as well as a high amount of PEG signal, 
leading to the cyan color in the box. 
Additionally, at there is evidently more PEG 
staining on the surface of the section (left) than 
in the mid-section images (top right and bottom 
right) implying higher membrane affinity than 
cytosolic affinity.  











The images presented in the results section contain qualitative information detailing the 
extent of tumor growth, the endothelial vascularization of the brain’s tissues, including 
within the implanted tumor, and the location of the PEG within the brain as an indication of 
where the novel nanoparticles end up. All of this information is potentially useful to 
investigators interested in increasing the efficacy of nanoparticle related cancer therapies, and 
specifically radiation therapy. In particular, understanding the precise localization of the 
novel INPs is important because it can allow researchers to determine differences in 
treatment success based on nanoparticle localization. For example, it could allow researchers 
to discern differences in treatments utilizing INPs that localize in the membrane, cytosol, or 
the nucleus, and what phenomena allow for specific localization. 
From the 10X images it is clear the PEGylated nanoparticles accumulate in the tumor 
region. This is a well-documented phenomenon called the enhanced permeability and 
retention (EPR) effect [13] of nanoparticles and other molecules and it is caused by the 
Chart	1:	Pearson's	Correlation	Coefficients 
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presence of incomplete basal membranes and gaps in endothelial cells frequently present in 
tumor vasculature [19, 20]. Thus, regardless of the size of the PEG ligands on the INP, there 
is a strong propensity for nanoparticles to accumulate in the tumor interstitium, given they 
have enough time to circulate in the blood and eventually deposit there. Additionally, Figure 
6 supports the notion that once in the interstitium, the PEGylated INPs can translocate 
through diffusion or convection to noncancerous regions within the invasive tumor [19]. This 
is an especially important revelation in regards to determining the final efficacy of radiation 
therapy, because it demonstrates there is potential for the radiation dose enhancement of 
heavy atom based nanoparticles to also effect noncancerous tissue within a tumor.  
One of the major pieces of evidence this research supports is the localization of the 
PEGylated nanoparticles on the exterior of groups of cells and in the voids between cells 
where tight junctions are not present. Additionally, the absence of the PEG signals within the 
cells, specifically in regions also expressing tdTomato, should be noted. This supports the 
conclusion that these INPs do not penetrate the cell in detectable quantities within 24 hours 
of the last INP injection. There are several possible explanations for this effect, with many 
relating to the PEG ligands on each INP. In order to increase the circulation time of the 
nanoparticles, PEG is attached because it is relatively hydrophilic for a hydrocarbon polymer, 
due to its polar ether linkages, allowing it to remain in the blood for longer periods. In 
addition, PEG often acts to mask the nanoparticles from non-specific cellular uptake by 
decreasing protein adsorption to the nanoparticle underneath, leading to an increase in 
specific cellular uptake if conjugated biomolecules are present and an increase in the amount 
of nanoparticles that eventually deposit in the interstitium of a tumor [14, 16, 17, 19]. PEG 
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also increases the hydrodynamic radius of the nanoparticle inhibiting renal excretion and 
allowing a further increase in circulation time.  
Nonetheless, though the ligation of PEG to the INPs has the effect of potentially 
increasing the number of nanoparticles that may deposit in the tumor, it may also limit the 
amount that enters the cells via phagocytosis or pinocytosis. This is because the PEG coating 
inhibits protein adsorption and thus receptor-mediated endocytosis. Thus, PEGylated 
nanoparticles may become trapped in the interstitium and not permitted readily into the cells. 
Additionally, there is some evidence that if the INP is slightly ionic in character, the 
amphiphilic nature of the PEGylated INP may allow it to remain within cell membranes and 
resist passing into the cytosol [16]. 
 The localization of the INPs in the vasculature of the brain both within and outside of the 
tumor region is supported in the images presented, especially in Figure 2 and Figure 3. 
Though, the PEG signal is detectable when far from the tumor site, it is not nearly as 
widespread and does not exist as much outside of the vasculature as within the tumor region. 
Nonetheless, substantial deposition must occur in the vasculature as Figure 3 supports, 
showing more complete vessels than the endothelial marker CD31 staining is capable of. 
This is evident because in the same region CD31 and PEG staining overlap, however PEG 
staining continues to mark the blood vessels while CD31 ceases to completely do so. This 
could be because more PEG molecules are present in these vessels at the surface exposed to 
the incubation fluid, where as CD31 is a protein used for intracellular junctions and thus may 
be secluded from the surface in many locations. Likewise, within the tumor region there is 
some evidence that supports the hypothesis that the INPs are localizing in the vasculature, 
however the CD31 staining is rather diffuse and many clear vessels are not always easy to 
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identify. Additionally, the vast presence of PEG signal in the tumor may mask some of the 
specificity of the accumulation within the tumor vasculature. It should also be noted that 
when the cells are implanted an injury is created leading to a small amount of bleeding. If 
this injury does not fully heal by the time the INP is injected, then there is a chance the injury 
can contribute to the wide distribution of INP within and around the tumor site.  
Additionally, it is worth discussing the ordinary size of glioblastomas found in human 
brains and the proportional size presented in this study. In humans, glioblastoma tumors are 
most often found occupying a total of about 2 percent of the brain’s entire volume. This is 
rather large and when projected into a mouse model corresponds to roughly 9 microliters of 
tumor volume out a total brain volume of 450 microliters. In this study, the cross section 
presented in the tile-scan image shows a tumor with an approximate average radius of 1.37 
mm. If the tumor is assumed to be spherical in shape then the total volume of the tumor is 
roughly 10.8 microliters. This is slightly larger than the average but not by a great deal and 
thus the tumor could likely be expected to behave in a similar manner in regards to INP 
uptake. Also it should be noted that the U-1242MG cell line is a very invasive tumor and 
potential satellite tumors are possible in regions of the brain separated from the main tumor 
mass. If this occurs, the physical and chemical structure of the tumor microenvironments 
may be altered in more than one region of the brain leading to a potential increase in the 
overall INP retention. This is important because there could be regions of the imaged section 
affected by tumor cells not in the plane of the imaged section but in the same 
microenvironment.  
Though this imaging study showed some clear results and evidence in support of where 
the novel INPs localize in murine brains implanted with U-1242MG tumors, there might 
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need to be more work performed in order to rule out several alternative explanations for the 
results obtained. First, in order to confirm or deny the conclusion that the INPs localize 
solely outside of the cells and do not penetrate the cell membrane, a staining protocol in 
which the cell membranes are made permeable to allow for intracellular immunostaining to 
be performed could be done. This could be done with permeabilizing molecules like saponin, 
Triton X-100, or Tween 20, that make either reversible or permanent holes in the cell 
membranes allowing both primary and secondary antibodies to diffuse through the cell 
membrane and attach to intracellular antigens, possibly including intracellular PEG [24].  
Another factor that may obscure the results is that the endothelial marker protein CD31 
(also known as PECAM1) used in this imaging is also expressed on the surfaces of many 
blood components including platelets and white blood cells, specifically monocytes, 
neutrophils and some T cells, though these mice lack T cells [25]. If these cells were able to 
exit the tumor via the leaky vasculature and remain in the interstitium, there could be non-
specific staining occurring. If so, then within the tumor region it may be harder to detect 
blood vessels present and thus staining protocols with antibodies specific for platelet or white 
blood cell surface proteins could be used to confirm or deny their presence within a tumor, or 
a more specific endothelial cell marker could be selected such as CD34, CD54, CD45, 
VEGF-R2, vWF, Tek, or several others [26].  
Lastly, the duration between when the mice received their INP injections and when the 
tissue was harvested could have a significant impact in the total uptake of the deposited INPs. 
In order to determine the uptake over time of the INP into the tumor cells, an experiment 
assessing the differences in cellular uptake of the INPs versus duration between injection and 
tissue harvesting could be performed.  
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VI. Conclusion:  
Ultimately, through the use of both low-power and high-power conventional and confocal 
fluorescence light microscopy techniques, substantial preliminary evidence in the localization 
of novel Iodine-based nanoparticles within murine brains containing implanted human 
glioma U-1242MG tumors was obtained. This was done through the probing of the 
endothelial cell marker CD31, the tumor-expressed fluorescent protein tdTomato, and the 
INP conjugated poly(ethylene glycol), and their respective immunocytochemistry primary 
and secondary antibodies. Among such evidence was that the novel INPs from Nanoprobes 
Inc. localized primarily in and around the tumor region nearly uniformly throughout 
cancerous and noncancerous cells. Additionally, the INPs localized primarily in the brain’s 
vasculature when found outside of the tumor region. There is also evidence that the INPs did 
not enter the cells in significant quantities but rather remained in the interstitium and along 
the exterior of cell clusters. In the end, though there are some additional procedures that can 
be performed to further confirm the results obtained, this evidence may still support further 
research into how these nanoparticles may be used in the treatment of cancer through 
radiation dose enhancement. Additional treatment methods including drug delivery, 
photothermal dose enhancement, and future nanoparticle based therapies and technologies 
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